Physician profile
Eric Tan
NPI 1144995754
$951.13
in general payments reported to CMS, 2019-2025
13 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $195 · 2023: $153 · 2024: $177 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.08 | 2021-2025 | Jardiance |
| Abbvie INC. | $169.79 | 2021-2025 | |
| Exact Sciences Corporation | $146.40 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $143.93 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $86.52 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $48.41 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $33.45 | 2024-2025 | Mounjaro, Jardiance |
| Phadia US INC. | $31.28 | 2022-2024 | Immunocap |
| Tersera Therapeutics LLC | $25.00 | 2025 | Zoladex |
| Sanofi-Aventis U.S. LLC | $21.76 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.47 | 2023 | Gvoke Hypopen |
| Indivior INC. | $16.32 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.